The efficacy of standard glioblastoma (GBM) treatments has been limited due to the highly
immunosuppressive tumor immune microenvironment, interpatient tumor heterogenicity and …

Glioblastoma is an unmet clinical need. Local treatment strategies offer advantages, such as
the possibility to bypass the blood–brain barrier, achieving high drug concentrations at the …

The development of chemoimmunotherapy with reduced systemic toxicity using local
formulations is an effective strategy for combating tumor recurrence. Herein, we reported a …

The unique cancer-associated immunosuppression in brain, combined with a paucity of
infiltrating T cells, contributes to the low response rate and poor treatment outcomes of T cell …

Immunotherapies have revolutionized intervention strategies for many primary cancers, but
have not improved the outcomes of glioblastoma multiforme (GBM), which remains one of …

It is well known that glioma is currently the most malignant brain tumor. Because of the
existence of blood-brain barrier (BBB) and tumor cell heterogeneity, systemic chemotherapy …

Glioblastoma multiforme (GBM), a prevalent brain cancer with high mortality, is resistant to
the conventional single-agent chemotherapy. In this study, we employed a combination …

Immunotherapy efficacy as monotherapy is negligible for glioblastoma (GBM). We
hypothesized that combining therapeutic vaccination using a plasmid encoding an epitope …

Glioblastoma, the most common malignant tumor of the central nervous system, readily
relapses after surgery. Based on the CD47-SIRPα axis, we designed and implanted a …

The outcome for glioblastoma patients remains dismal for its invariably recrudesces within 2
cm of the resection cavity. Local immunotherapy has the potential to eradicate the residual …